11.08.2023 | ASO Author Reflections
ASO Author Reflections: Sequence of Treatment in Clinically Node-Negative T1 Triple-Negative Breast Cancer
verfasst von:
Kai Huang, MD, James W. Jakub, MD, Sarah A. McLaughlin, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 13/2023
Einloggen, um Zugang zu erhalten
Excerpt
With the advances in chemotherapy and understanding of the molecular breast cancer subtypes, neoadjuvant chemotherapy (NACT) has been increasingly used in operable early breast cancer to downstage the primary tumor and axillary nodes, allowing for de-escalation of local regional interventions. Triple-negative breast cancer (TNBC) and HER2Neu overexpressed molecular subtypes are the most responsive to systemic chemotherapy. Tumor response after NACT can guide subsequent adjuvant therapy, and a pathologic complete response (pCR) after NACT is associated with improved survival.
1 …